About: Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 April 1999

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у квітні 1999 (uk) im April 1999 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'abril de 1999 (ast) scientific article published on 01 April 1999 (en)
publication date	wds:Q77222399-6A73CD2C-1B3F-430A-82F3-2A5345A4D00C
publication date	1999-04-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q77222399-3232FBCD-E22D-40DA-B7BC-0770A0F242E6
language of work or name	English
cites work	wds:Q77222399-00CEAD04-2E56-4DDF-8081-7F2234E9C64B wds:Q77222399-1312207A-517E-44EE-AC77-7E3AEA6A038A wds:Q77222399-5AD2F9D0-599F-462C-8164-15DCC62EEE66 wds:Q77222399-66D5582C-8042-43AE-BF3A-AA45FA9E8D3B wds:Q77222399-68A4C598-C849-452F-B325-C5922D593007 wds:Q77222399-68EB94FB-830D-4871-96ED-0CD8B07BC667 wds:Q77222399-7551D51D-F073-4907-BC55-D31048F7E03F wds:Q77222399-7BB771F8-18AC-4183-B462-F4600576BB42 wds:Q77222399-7E5D8F4F-702C-4550-8CFF-07864E7EDAC4 wds:Q77222399-8B8548BB-FCE2-4202-AD19-8B45DD49F701 wds:Q77222399-8CF58007-4B1E-41AA-81C2-A23B4A3567A0 wds:Q77222399-B075E604-818C-42EA-AA50-77DB671EF09E wds:Q77222399-BD532BCD-F0F8-48CE-9092-DA79EF9C3835 wds:Q77222399-D1EDA7DC-7AC7-4B38-AE05-40CBA35773C6 wds:Q77222399-E6E992FA-BC83-45F9-B7BF-3DCDE1994713 wds:Q77222399-EEA62DA1-7C3E-438C-86BC-2472FF87D37F
cites work	Management of pulmonary disease in patients with cystic fibrosis Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-Placebo Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone Standardization of lung function testing in children. Proceedings and Recommendations of the GAP Conference Committee, Cystic Fibrosis Foundation A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? Selective media for the quantitation of bacteria in cystic fibrosis sputum. Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication
author name string	wds:Q77222399-0538E091-1916-4A68-86FB-D6F605621408 wds:Q77222399-1AFABB9F-6297-4E90-A020-19931234776D wds:Q77222399-36DA786D-409A-4445-8743-AE96E33B0AB7 wds:Q77222399-3DFFED55-195E-4DAD-9951-023E30B366F1 wds:Q77222399-46ECE35A-7434-4733-BDB6-9A058EAD0E5E wds:Q77222399-55236132-4CA2-465B-AE8B-B9972B19F58B wds:Q77222399-8413B7D4-9848-46FA-A4D8-D64B2803B718 wds:Q77222399-8BB52062-AA0E-45D5-9A68-7DD31E7A7F1A wds:Q77222399-962222C8-15DB-49F6-A6B2-03494E28EFFE wds:Q77222399-B637FA7C-3214-4F7A-B97C-057F17E2374B wds:Q77222399-CEB336B0-9FF3-421C-91B6-E293E8DF34F1 wds:Q77222399-EB1FD4F3-2CDC-4154-AAC6-2709B32F82EF wds:Q77222399-EF178686-42BE-4CFA-8FD4-5F3A1AFEA20F wds:Q77222399-FD89258F-0CD9-46FF-90F1-A31085C0400C
author name string	B Hilman T Rubio A L Smith R Yogev M Marks R Moss H D Wilson B Ramsey J Williams-Warren E Gore R Wilmott D Goldmann C Doershuk G Redding
rdfs:label	Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis (en) Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis (nl)
skos:prefLabel	Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis (en) Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis (nl)
name	Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis (en) Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis (nl)
title	wds:Q77222399-EDE8021A-4DBC-4339-B0D4-B37963F83AE5
title	Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis (en)
page(s)	wds:Q77222399-290B8123-22F9-4E8C-BC31-D1B6C12AD2C3
page(s)	413-421
instance of	wds:Q77222399-B3186842-54FE-4E9F-90F7-94AC5E63ABFE
instance of	scholarly article
main subject	wds:Q77222399-3541DD17-1CFC-401E-A5FF-4450A794C8FC
main subject	cystic fibrosis
PubMed ID	wds:Q77222399-9A8B8ACA-3E6F-4DAB-9A25-39C9AD7FA2FE
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10190914
PubMed ID	10190914
published in	wds:Q77222399-BD02A88D-CC83-49B8-A896-51090AC98FE9
published in	The Journal of Pediatrics
issue	wds:Q77222399-416AFCFB-FB6F-42B9-9DF0-03068E9D0429
volume	wds:Q77222399-B37A0256-87C4-4E8D-8CFF-147FB9E91A6B
issue	4
volume	134
DOI	wds:Q77222399-BB608E4C-8BD9-4B65-B27F-AF700FA598DE
DOI	http://dx.doi.org/10.1016/S0022-3476(99)70197-6
DOI	10.1016/S0022-3476(99)70197-6
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q77222399
is cites work of	Patient-reported outcomes in cystic fibrosis Systematic reviews and lifelong diseases A protease-resistant catalase, KatA, released upon cell lysis during stationary phase is essential for aerobic survival of a Pseudomonas aeruginosa oxyR mutant at low cell densities

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software